Scholarlink

<p>Visceral crisis in advanced breast cancer (ABC) represents a major challenge. Here we conducted a phase 2 study to evaluate dalpiciclib plus endocrine therapy (ET) in women with HR<sup>+</sup>/HER2<sup>−</sup> ABC experiencing visceral crisis. The primary endpoint was the 6-month survival rate; secondary endpoints included overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), 3-month treatment failure rate (TFR), duration of disease control (DDC), objective response rate (ORR), disease control rate (DCR) and safety. Among 53 participants, 49 survived beyond 6 months, yielding a 6-month survival rate of 92.5% (95% confidence interval (CI): 81.8–97.9), meeting the primary endpoint. The ORR was 26.4%, DCR was 79.2% and 3-month TFR was 22.6%. The median PFS was 11.2 months (95% CI: 7.6–19.3), DDC was 14.1 months (95% CI: 8.4–21.5) and TTF was 10.2 months (95% CI: 6.4–15.6); the median OS was not reached. The most common grade ≥3 adverse events were neutrophil count decreased (77.4%) and white blood cell count decreased (54.7%). Exploratory analyses indicated that a baseline monocyte-derived cfDNA level below 0.0581 was associated with worse OS (hazard ratio: 4.79, 95% CI: 1.05–45.47, <i>P</i> = 0.0394), indicating a ‘molecular crisis’. These findings support further evaluation of dalpiciclib plus ET in persons with ABC with visceral crisis (ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT05431504">NCT05431504</a>).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dalpiciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial

  • 期刊论文

  • 发表日期：

    2026年7月21日

查看全文
  • Hongnan Mo,
  • Yuee Teng,
  • Li Cai,
  • Huihui Li,
  • Xinhong Wu,
  • Jing Yao,
  • Yu Wang,
  • Dan Lv,
  • Xuenan Peng,
  • Shuchun Wang,
  • Rongrong Chen,
  • Xin Yi,
  • Qingyao Shang,
  • Youwen He,
  • Ji Liu,
  • Zheng Pang,
  • Tianyu Feng,
  • Fei Ma

摘要

Visceral crisis in advanced breast cancer (ABC) represents a major challenge. Here we conducted a phase 2 study to evaluate dalpiciclib plus endocrine therapy (ET) in women with HR+/HER2− ABC experiencing visceral crisis. The primary endpoint was the 6-month survival rate; secondary endpoints included overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), 3-month treatment failure rate (TFR), duration of disease control (DDC), objective response rate (ORR), disease control rate (DCR) and safety. Among 53 participants, 49 survived beyond 6 months, yielding a 6-month survival rate of 92.5% (95% confidence interval (CI): 81.8–97.9), meeting the primary endpoint. The ORR was 26.4%, DCR was 79.2% and 3-month TFR was 22.6%. The median PFS was 11.2 months (95% CI: 7.6–19.3), DDC was 14.1 months (95% CI: 8.4–21.5) and TTF was 10.2 months (95% CI: 6.4–15.6); the median OS was not reached. The most common grade ≥3 adverse events were neutrophil count decreased (77.4%) and white blood cell count decreased (54.7%). Exploratory analyses indicated that a baseline monocyte-derived cfDNA level below 0.0581 was associated with worse OS (hazard ratio: 4.79, 95% CI: 1.05–45.47, P = 0.0394), indicating a ‘molecular crisis’. These findings support further evaluation of dalpiciclib plus ET in persons with ABC with visceral crisis (ClinicalTrials.gov: NCT05431504).